Prostate Reirradiation Toxicity Outcomes Feasibility Study
Research type
Research Study
Full title
Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility randomised clinical trial investigating toxicity outcomes following reirradiation with ultra-hypofractionated external beam radiotherapy vs. high dose rate brachytherapy
IRAS ID
297060
Contact name
Ann Henry
Contact email
Sponsor organisation
University of Leeds
ISRCTN Number
ISRCTN12238218
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Prostate cancer is the most common UK male cancer. Radiotherapy is a type of cancer treatment that involves using radiation energy to kill cancer cells. The two ways to deliver radiation are from a machine outside the body (external beam radiation) or from internal sources placed within the body (brachytherapy) while the patient is asleep (requires a general anaesthetic).
Despite these treatments, in some patients the cancer can come back and most of these cancers will come back within the prostate gland itself, which is called a local recurrence. Current research suggests treating the recurrence with a second course of radiation given using either brachytherapy or external beam may be better than other options such as surgery as there are less side effects. Brachytherapy and external beam radiotherapy for recurrence have not been directly compared and the side effects people experience after treatment have not been fully described.
External beam radiation can now be delivered so that more intense radiation doses are directed to the cancer in a more accurate way by using daily imaging. This new treatment is called ultra-hypofractionated or stereotactic ablative radiotherapy (SABR). Although it has been widely used for other indications, we do not know how effective it is for treating prostate cancer recurrence. We also have limited information on treatment side effects.
We want to check if participants are happy to be randomised to either treatment to see if a larger study may be possible. We also want to assess how the radiation treatment impacts on people’s long term quality of life by regular follow-ups and questionnaires. This means future patients will have better information when making treatment choices.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
21/YH/0305
Date of REC Opinion
18 Jan 2022
REC opinion
Further Information Favourable Opinion